Jacobs Levy Equity Management’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.36M | Sell |
1,213,736
-989,587
| -45% | -$1.11M | 0.01% | 696 |
|
|
2025
Q1 | $1.74M | Buy |
2,203,323
+616,336
| +39% | +$487K | 0.01% | 691 |
|
|
2024
Q4 | $2.62M | Sell |
1,586,987
-913
| -0.1% | -$1.51K | 0.01% | 544 |
|
|
2024
Q3 | $5.56M | Sell |
1,587,900
-106,317
| -6% | -$372K | 0.02% | 427 |
|
|
2024
Q2 | $5.56M | Sell |
1,694,217
-305,605
| -15% | -$1M | 0.02% | 437 |
|
|
2024
Q1 | $14.7M | Sell |
1,999,822
-616,998
| -24% | -$4.53M | 0.07% | 243 |
|
|
2023
Q4 | $9.79M | Buy |
2,616,820
+227,697
| +10% | +$852K | 0.05% | 304 |
|
|
2023
Q3 | $5.06M | Buy |
2,389,123
+54,005
| +2% | +$114K | 0.03% | 375 |
|
|
2023
Q2 | $11.1M | Buy |
2,335,118
+991,489
| +74% | +$4.72M | 0.06% | 265 |
|
|
2023
Q1 | $7.66M | Buy |
+1,343,629
| New | +$7.66M | 0.05% | 326 |
|
|
2017
Q4 | – | Sell |
-16,300
| Closed | -$65K | – | 1010 |
|
|
2017
Q3 | $65K | Sell |
16,300
-33,704
| -67% | -$134K | ﹤0.01% | 926 |
|
|
2017
Q2 | $162K | Sell |
50,004
-10,700
| -18% | -$34.7K | ﹤0.01% | 865 |
|
|
2017
Q1 | $276K | Sell |
60,704
-33,278
| -35% | -$151K | 0.01% | 739 |
|
|
2016
Q4 | $236K | Sell |
93,982
-30,490
| -24% | -$76.6K | ﹤0.01% | 808 |
|
|
2016
Q3 | $388K | Sell |
124,472
-54,175
| -30% | -$169K | 0.01% | 755 |
|
|
2016
Q2 | $304K | Sell |
178,647
-25,800
| -13% | -$43.9K | 0.01% | 879 |
|
|
2016
Q1 | $368K | Buy |
204,447
+167,194
| +449% | +$301K | 0.01% | 814 |
|
|
2015
Q4 | $126K | Buy |
+37,253
| New | +$126K | ﹤0.01% | 728 |
|